ReviewClinical pharmacology : advances and applications2013
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.
Review in Clinical pharmacology : advances and applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy.Pharmaceutics · 2023Review
- Targeting Cbl-b in cancer immunotherapy.Journal for immunotherapy of cancer · 2023Review
- Advanced Acral Melanoma Therapies: Current Status and Future Directions.Current treatment options in oncology · 2022Review
- Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.Frontiers in immunology · 2022Review
- 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer.International journal of molecular sciences · 2021Review
- Article
- CD137Cancers · 2021Review
- Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma.International journal of clinical and experimental pathology · 2021Article
- Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.Cancer immunology, immunotherapy : CII · 2019Article
- Immunoregulatory functions of VISTA.Immunological reviews · 2017Review
- Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.Frontiers in immunology · 2017Article
- Advances in immunotherapy for melanoma management.Human vaccines & immunotherapeutics · 2016Review
- Regulation of Bim in Health and Disease.Oncotarget · 2015Review
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent.The Journal of clinical investigation · 2015Article
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Immunotherapy · 2015Review
- Novel anti-melanoma treatment: focus on immunotherapy.Chinese journal of cancer · 2014Article
- Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.Clinical & translational immunology · 2014Review
- Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.PloS one · 2014Article
- Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity.Clinical pharmacology : advances and applications · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. CD137 (also known as 4-1BB) a member of the tumor necrosis factor (TNF) receptor superfamily, is an activation-induced T cell costimulator molecule. Growing evidence indicates that anti-CD137 monoclonal antibodies possess strong antitumor properties, the result of their powerful capability to activate CD8+ T cells, to produce interferon (IFN)-γ, and to induce cytolytic markers. Combination therapy of anti-CD137 with other anticancer agents, such as radiation, has robust tumor-regressing abilities against nonimmunogenic or poorly immunogenic tumors. Of importance, targeting CD137 eliminates established tumors, and the fact that anti-CD137 therapy acts in concert with other anticancer agents and/or radiation therapy to eradicate nonimmunogenic and weakly immunogenic tumors is an additional benefit. Currently, BMS-663513, a humanized anti-CD137 antibody, is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, ovarian cancer, and B-cell malignancies. In this review, we discuss the basis of the therapeutic potential of targeting CD137 in cancer treatment, focusing in particular, on BMS-663513 as an immune costimulatory monoclonal antibody for melanoma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.